700087Novel Intravenous ibuprofen formulation for the treatment of pain and fever in adults and childrenClosedGRD Proof of MarketInnovate UKAcute pain is a significant problem and can occur following acute illness or disease processes, trauma or operative procedures. Proveca’s objective is to develop an intravenous (IV) formulation of an off-patent drug for the treatment of pain and fever in adults and children. They will undertake the required clinical studies and apply for a license to target the adult market in the UK and EU as well as for a Paediatric Use Marketing Authorisation (PUMA). The global pain market recorded sales of $22.0 billion in 2010, rising at a CAGR of 8.9%. About 4.2 million surgical procedures are carried out on the NHS in England according to the Royal College of Surgeons. A study revealed that 80% of patients experienced acute pain after surgery. The innovation lies in developing a new licensed IV formulation, which will involve conducting the required clinical trials to assess the drug efficacy. Pharmacokinetic studies will be required to secure an adult license for pain and possibly fever. To obtain a paediatric licence through a PUMA, Proveca will need to conduct an efficacy study as well as some pharmacokinetic work. The key objective of this Proof of Market project is to assess the commercial viability of Proveca’s new IV formulation for the relief of pain and fever with adults and children, to establish a full validation of the UK and EU market, gaining a thorough understanding of the real needs and requirements of the patients, clinicians, GPs, pharma companies and other stakeholders for the novel IV formulation. The early mapping of the market opportunities will significantly accelerate the development and realisation of the project and the European scope of the research will help Proveca to understand the wider market requirements.